ClinicalTrials.gg
Active, not recruitingNCT06372496PERFORMUpdated Oct 6, 2026Results posted

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

A Phase 4 interventional study of Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate and Inhaled corticosteroids/long-acting beta-2 agonists in Asthma, sponsored by GlaxoSmithKline. Active, not recruiting at 117 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Updated Oct 6, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,358
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
2nd of 40
1,358 · median 102
Started
2024
the only one that year
Phase 4
6 of 40
none open now
Registered
40th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 2nd largest by enrollment, is the only one that started in 2024, is one of 6 in phase 4, and was the 40th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • FF/UMEC/VI
  • ICS/LABA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Has a diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2023 guidelines for at least 3 months prior to randomization.
  2. Participants who are either:

    • Currently untreated
    • Treated with daily maintenance ICS or ICS/LABA
  3. ACQ-6 score ≥1.5 at randomization.
  4. Participants able to perform technically acceptable and repeatable maneuvers (i.e., a minimum of 2 acceptable and 1 repeatable effort) at visit 2 (V2)
  5. Participants must be able to complete the study questionnaires.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Recent history of life-threatening asthma
  2. History of >1 severe exacerbation of asthma within 12 months prior to randomization.
  3. Women of that are not following at least one highly effective method of . This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
  4. A WOCBP must have a negative pregnancy test ≤7 days prior to randomization.
  5. Exposure to inhaler triple therapy [ICS + Long-acting muscarinic antagonist (LAMA) + LABA as Single inhaler triple therapy (SITT) or Multiple inhaler triple therapy(MITT)] and/or any LAMA-containing therapy within 12 months prior to randomization.
  6. Ongoing need for biologic therapy or recent use of a biologic therapy
  7. Participants with the diagnosis of , as per Global Initiative for Chronic Obstructive Lung Disease (GOLD 2024) guidelines.
  8. Participants whose current medications include RELVAR ELLIPTA and ARNUITY ELLIPTA are not eligible to enter the study.
  9. Participants who are medically unable to withhold their albuterol/salbutamol for 6 hours prior to spirometry testing
  10. Changes in asthma medication (e.g., maintenance ICS/LABA) within 3 months prior to randomization.
  11. Participants with a history of to any of the study medications
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,358 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]

    Participants with uncontrolled asthma were randomized to receive a once-daily (QD) fixed-dose combination of 100 microgram (mcg) fluticasone furoate (FF), 62.5 mcg umeclidinium (UMEC), and 25 mcg vilanterol (VI) via the Ellipta dry powder inhaler (DPI) for up to 24 weeks. At the discretion of the investigator, a subset of participants received the high-dose ICS-containing therapy, FF/UMEC/VI 200/62.5/25 instead. At any time during the study (post-randomization), participants were escalated to receive FF/UMEC/VI 200/62.5/25 mcg if their asthma control worsened significantly, defined as an increase in Asthma Control Questionnaire (ACQ-7) total score of \>0.5 from baseline and the physician determines increased Inhaled Corticosteroid \[ICS\] is ethically necessary.

    Drug: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

  • Active comparator
    Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA]

    Participants with uncontrolled asthma were randomized to receive Inhaled Corticosteroid \[ICS\]/Long-acting beta-2 agonist \[LABA\] based on usual care as per the country specific regulatory labels up to 24 weeks. At the discretion of the investigator, a subset of participants received high-dose ICS/LABA. At any time during the study (post-randomization), participants were escalated to receive high dose ICS/LABA if their asthma control worsened significantly, defined as an increase in ACQ-7 total score of \>0.5 from baseline and the physician determines increased ICS is ethically necessary.

    Drug: Inhaled corticosteroids/long-acting beta-2 agonists

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value

    Time frame: Baseline (Day 1) and at Week 24

Secondary outcomes

  1. Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.

    Time frame: Baseline (Day 1) and at Week 24

  2. Percentage of Participants Achieving the Composite Endpoint (Optimized) at Week 52

    The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 \>= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks

    Time frame: Baseline (Day 1) and at Week 52

  3. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

    Time frame: Baseline (Day 1) and at Week 52

  4. Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.

    Time frame: Baseline (Day 1) and at Week 24

  5. Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

    Time frame: Baseline (Day 1) and at Week 52

  6. Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.

    Time frame: Baseline (Day 1) and at Week 24

  7. Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

    Time frame: Baseline (Day 1) and at Week 52

  8. Percentage of Participants Achieving >= 0.5 Point Improvement (Decrease) From Baseline for the ACQ-7 Score at Week 52

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  9. Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24

    The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.

    Time frame: Baseline (Day 1) and at Week 24

  10. Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 52

    The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  11. Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.

    Time frame: Baseline (Day 1) and at Week 24

  12. Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  13. Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value

    Time frame: Baseline (Day 1) and at Week 24

  14. Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  15. Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24

    The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  16. Change From Baseline (CFB) in the ACQ-6 Total Score at Week 52

    The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  17. Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  18. Change From Baseline (CFB) in the ACQ-5 Total Score at Week 52

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  19. Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24

    The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  20. Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52

    The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  21. Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA Prior to Randomization at Week 52

    The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.

    Time frame: Baseline (Day 1) and at Week 52

  22. Percentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving no Treatment Prior to Randomization at Week 52

    The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).

    Time frame: Baseline (Day 1) and at Week 52

  23. Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24

    AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  24. Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 52

    AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  25. Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24

    AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  26. Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 52

    AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  27. Change From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24

    WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

    Time frame: Baseline (Day 1) and at Week 24

  28. Change From Baseline in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment Questionnaire at Week 52

    WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  29. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Among Participants on ICS/LABA Prior to Randomization

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.

    Time frame: Baseline (Day 1) and Week 24

  30. Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 Among Participants on ICS/LABA Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.

    Time frame: Baseline (Day 1) and at Week 24

  31. Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 Among Participants on ICS/LABA Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  32. Change From Baseline in the ACQ-7 Total Score at Week 24 Among Participants on ICS/LABA Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

    Time frame: Baseline (Day 1) and at Week 24

  33. Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 Among Participants on ICS/LABA Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  34. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 for Participants With no Treatment Prior to Randomization

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

    Time frame: Baseline (Day 1) and Week 24

  35. Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 for Participants With no Treatment Prior to Randomization.

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of \<=0.75 indicates well-controlled asthma and a score \>=1.5 indicates poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

    Time frame: Baseline (Day 1) and at Week 24

  36. Percentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 for Participants With no Treatment Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<=0.75 indicates is well-controlled asthma; and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

  37. Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24 for Participants With no Treatment Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

    Time frame: Baseline (Day 1) and at Week 24

  38. Change From Baseline (CFB) in the ACQ-7 Total Score at Week 52 for Participants With no Treatment Prior to Randomization

    The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

    Time frame: Baseline (Day 1) and at Week 52

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneFluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Started682676
Safety analysis set (saf)- modified 1631605
Full analysis set - modified 1619617
Completed4238
Not completed640638
Withdrew: Other12
Withdrew: Withdrawal by subject2222
Withdrew: Site closed1517
Withdrew: Protocol violation10
Withdrew: Physician decision20
Withdrew: Lost to follow-up1725
Withdrew: Death01
Withdrew: Adverse event11
Withdrew: Excluded from fas-modified 1 due to data integrity concerns at the site5954
Withdrew: Randomized but not treated45
Withdrew: Ongoing518511

Outcome measures

PrimaryChange From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Liter (L)
Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
Liter (L)Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 240.178 ± 0.01980.110 ± 0.0196
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · p = <0.0001 · Mean difference (net): 0.068 · 95% CI 0.036 to 0.099
SecondaryPercentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation).ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=)0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 24
Percentage of ParticipantsFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Percentage of Participants Achieving Greater Than Equal to (>=) 0.5 Point Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) at Week 247971.8
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · Regression, Logistic · p = 0.0044 · Odds ratio (or): 1.47 · 95% CI 1.13 to 1.92
SecondaryPercentage of Participants Achieving the Composite Endpoint (Optimized) at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: Change from baseline in trough FEV1 \>= 100 milliliter (mL) at Week 52, Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52, No severe asthma exacerbations over 52 weeks and oral corticosteroids (OCS)-free over 52 weeks

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24
Percentage of ParticipantsFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Percentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 2446.029.5
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · Odds ratio (or): 2.01 · 95% CI 1.58 to 2.56
SecondaryPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value. Percentage values are rounded-off.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24
Percentage of ParticipantsFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Percentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 2465.951.5
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · Odds ratio (or): 1.77 · 95% CI 1.41 to 2.24
SecondaryPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1).

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >= 0.5 Point Improvement (Decrease) From Baseline for the ACQ-7 Score at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to (\<=) 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>= 1.5 indicates poorly controlled asthma. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded off.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 24
Percentage of ParticipantsFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 2480.977.0
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · Odds ratio (or): 1.26 · 95% CI 0.95 to 1.67
SecondaryPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-6 Score at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. A decrease in ACQ-6 score from Baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Percentage values are rounded-off.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24
Percentage of ParticipantsFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Percentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 2480.175.2
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · Odds ratio (or): 1.33 · 95% CI 1.01 to 1.75
SecondaryPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/ limitation. Higher scores indicated more limitations and lower scores with better asthma control. Higher score indicates worse symptoms. Greater than or equal to 0.5 point decrease from Baseline suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-7 Total Score at Week 24

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24
Scores on a scaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in the ACQ-7 Total Score at Week 24-1.42 ± 0.054-1.25 ± 0.053
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · Mean difference (net): -0.17 · 95% CI -0.25 to -0.08
SecondaryChange From Baseline (CFB) in the ACQ-7 Total Score at Week 52

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-6 Total Score at Week 24

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24
Scores on a scaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in the ACQ-6 Total Score at Week 24-1.58 ± 0.059-1.42 ± 0.058
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · Mean difference (net): -0.16 · 95% CI -0.25 to -0.06
SecondaryChange From Baseline (CFB) in the ACQ-6 Total Score at Week 52

The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. ACQ-6 consists of 6 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. Mean scores of \<=0.75 indicate well-controlled asthma, scores between 0.75 and 1.5 indicate partially controlled asthma, and scores \>=1.5 indicate poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-5 Total Score at Week 24

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24
Scores on a scaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in the ACQ-5 Total Score at Week 24-1.76 ± 0.064-1.60 ± 0.063
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · Mean difference (net): -0.16 · 95% CI -0.26 to -0.06
SecondaryChange From Baseline (CFB) in the ACQ-5 Total Score at Week 52

The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). The overall ACQ-5 response option is the mean score of all 5 questions representing 0=no impairment/limitation and 6=total impairment/limitation. Higher scores indicated more limitations and lower scores indicated better asthma control. Higher score indicates worse symptoms. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16 to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 24
Scores on a scaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 245.92 ± 0.2695.35 ± 0.265
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · Mean difference (net): 0.57 · 95% CI 0.14 to 1.00
SecondaryChange From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52

The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled) with higher scores indicating better control. Total ACT score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 15 suggests that the participant's asthma is poorly controlled, a score of 16-to 19 suggests that the participant's asthma is somewhat controlled, and a score of 20 to 25 suggests that the participant's asthma is well controlled. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA Prior to Randomization at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving ICS/LABA prior to randomization.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving the Composite Endpoint (Optimized) Subset on Participants Receiving no Treatment Prior to Randomization at Week 52

The 4-point composite endpoint is defined as meeting the following criteria: 1. Change from baseline in trough FEV1 ≥ 100 mL at Week 52; 2. Controlled asthma based on ACQ-5 total score \<= 1.5 at Week 52; 3. No severe asthma exacerbations over 52 weeks; 4. OCS-free over 52 weeks. Subset on participants receiving no treatment prior to randomization (no ICS-containing therapy within the 3 months prior to randomization).

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 24
Scores on a ScaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 241.42 ± 0.0691.27 ± 0.069
Statistical analysis
  • Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI] vs Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA] · ANCOVA · Mean difference (net): 0.15 · 95% CI 0.03 to 0.26
SecondaryChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Total Score at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), environmental stimuli (4 items). For 32 items on questionnaire, response format consists of a 7-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." AQLQ-12 total score is defined as average of scores from all 32 questions; thus, total score ranges from 1="total impairment" to 7="no impairment". Higher score is better asthma-related health-related quality of life. Baseline is last non-missing value prior to or on prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24
Scores on a ScaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Symptoms1.61 ± 0.0731.45 ± 0.072
Environmental Stimuli1.17 ± 0.0921.03 ± 0.091
Activity Limitation1.32 ± 0.0711.16 ± 0.071
Emotional Function1.41 ± 0.0871.28 ± 0.086
SecondaryChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 52

AQLQ-12 is a disease-specific, self-administered quality of life questionnaire used to evaluate impact of asthma treatments on quality of life of asthma sufferers. AQLQ-12 has 32 items in 4 domains: symptoms (12 items), environmental stimuli (4 items), activity limitation (11 items), emotional function (5 items). For 32 items on questionnaire, response format consists of a 7-point scale, where 1 indicates "total impairment" and 7 indicates "no impairment." AQLQ-12 each domain score total score is defined as average of scores from all the 32 questions from the respective domain; thus, each domain total score ranges from 1="total impairment" to 7=indicates "no impairment". Higher score is better asthma-related health-related quality of life. Each domain score is the mean of item scores within that domain. Baseline is last non-missing value prior to or on prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher values=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 24) value.

Time frame:
Baseline (Day 1) and at Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (CFB) in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 24
Scores on a scaleFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
Work time missed due to health-5.45 ± 0.895-4.80 ± 0.896
Impairment while working due to health-24.62 ± 1.750-24.24 ± 1.735
Overall work impairment due to health-25.45 ± 1.922-24.14 ± 1.904
Activity impairment due to health-27.44 ± 1.530-24.89 ± 1.511
SecondaryChange From Baseline in the Four Domains of the Asthma-specific Adaptation of the Work Productivity and Activity Impairment Questionnaire at Week 52

WPAI questionnaire measures impact due to poor health due to asthma on work and regular activities, yielding 4 percentage-based impairment scores, each ranges from 0 to 100%. Higher value=greater impairment and less productivity. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) =hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) =Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health =Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health =Q6 score (from 0 to 10) divided by 10\*100. Baseline is last non-missing value prior to or on prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Among Participants on ICS/LABA Prior to Randomization

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study (EOS) date.

Time frame:
Baseline (Day 1) and Week 24

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 Among Participants on ICS/LABA Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention. Per Protocol study's subgroup analysis design, analysis for this endpoint at Week 24 will be performed based on results from composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of EOS date.

Time frame:
Baseline (Day 1) and at Week 24

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 Among Participants on ICS/LABA Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control \& includes 5 symptom questions (nocturnal awakening,symptoms on waking in the morning,activity limitation,shortness of breath \& wheeze). Responses ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of the 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<= 0.75 is well-controlled asthma; a score between 0.75 and 1.5 is partially controlled asthma \& a score \>= 1.5 is poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in the ACQ-7 Total Score at Week 24 Among Participants on ICS/LABA Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as last non-missing value prior to or on prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

Time frame:
Baseline (Day 1) and at Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-7 Total Score at Week 52 Among Participants on ICS/LABA Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath, and wheeze) with response options ranging from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is the mean of the responses of the 7 items, ranges from 0 to 6. Higher score indicates poor control. A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 for Participants With no Treatment Prior to Randomization

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on treatment is defined as the last FEV1 value obtained prior to the morning dose of investigational product. Spirometry was performed to assess FEV1. Baseline is defined as the last acceptable/borderline acceptable pre-dose FEV1 obtained at the Randomization Visit (Visit 2/Day 1). Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

Time frame:
Baseline (Day 1) and Week 24

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 24 for Participants With no Treatment Prior to Randomization.

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of \<=0.75 indicates well-controlled asthma and a score \>=1.5 indicates poorly controlled asthma. \>= 0.5 point decrease from baseline is clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

Time frame:
Baseline (Day 1) and at Week 24

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving >=0.5 Points Improvement (Decrease) From Baseline for ACQ-7 at Week 52 for Participants With no Treatment Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze). Response ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation). ACQ-7 total score is mean of the responses of 7 items, ranges from 0 to 6. Higher score = poor control. A score of \<=0.75 indicates is well-controlled asthma; and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-7 Total Score at Week 24 for Participants With no Treatment Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in asthma control. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention. Per Protocol the study's subgroup analysis design, the analysis for this endpoint at Week 24 will be performed based on results from the composite (optimized) endpoint's Week 52 analysis. The pending results are expected to be available within 12 months of End of Study date.

Time frame:
Baseline (Day 1) and at Week 24

Results for this outcome have not been posted.

SecondaryChange From Baseline (CFB) in the ACQ-7 Total Score at Week 52 for Participants With no Treatment Prior to Randomization

The ACQ-7 measures 7 attributes of asthma control and consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze) with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than equal to 0.75 indicates well-controlled asthma, a score of between 0.75 and 1.5 indicates partially controlled asthma, and a score \>=1.5 indicates poorly controlled asthma. Baseline is defined as the last non-missing value prior to or on the prescription date of study intervention.

Time frame:
Baseline (Day 1) and at Week 52

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality, serious adverse events (SAE) and non-serious study intervention related adverse events (AE) were collected up to Week 24. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]0/631 (0%)10/631 (1.6%)18/631 (2.9%)
Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]1/605 (0.2%)7/605 (1.2%)4/605 (0.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
AsthmaRespiratory, thoracic and mediastinal disorders2/6311/605
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/6311/605
PneumoniaInfections and infestations1/6311/605
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/6311/605
Large intestine polypGastrointestinal disorders0/6311/605
Pancreatitis acuteGastrointestinal disorders0/6311/605
DeathGeneral disorders0/6311/605
Meniscus injuryInjury, poisoning and procedural complications0/6311/605
HypotensionVascular disorders0/6311/605
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/6310/605
Most frequent other events
Most frequent other events
EventFluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]
DysphoniaRespiratory, thoracic and mediastinal disorders18/6314/605

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]Total
Mean48.3 ± 1548.6 ± 15.2548.5 ± 15.12
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]Total
Female467452919
Male215224439
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fluticasone Furoate [FF]/ Umeclidinium [UMEC] / Vilanterol [VI]Inhaled Corticosteroid [ICS]/Long-acting Beta-2 Agonist [LABA]Total
American Indian or Alaska Native336
Asian193191384
White420421841
Not Reported101
Black or African American5955114
Native Hawaiian or Other Pacific Islander426
Multiple246
08

Study locations

117 sites
  • GSK Investigational Site
    Centreville, Alabama 35042, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Newark, Delaware 08901, United States
  • GSK Investigational Site
    Clearwater, Florida 33765-2150, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Miami, Florida 33173-3484, United States
  • GSK Investigational Site
    North Miami Beach, Florida 33169, United States
  • GSK Investigational Site
    Orlando, Florida 32819, United States
  • GSK Investigational Site
    Palm Springs, Florida 33406, United States
  • GSK Investigational Site
    Port Charlotte, Florida 33952, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    New Orleans, Louisiana 20852, United States
  • GSK Investigational Site
    Bangor, Maine 04401, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Warren, Michigan 48088, United States
  • GSK Investigational Site
    Missoula, Montana 59804, United States
  • GSK Investigational Site
    Papillion, Nebraska 68046, United States
  • GSK Investigational Site
    Brick, New Jersey 08724, United States
  • GSK Investigational Site
    Linwood, New Jersey 08221, United States
  • GSK Investigational Site
    New Windsor, New York 12553-7754, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28273, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27104, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    DuBois, Pennsylvania 15801-2277, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303-4225, United States
  • GSK Investigational Site
    Beaumont, Texas 77701, United States
  • GSK Investigational Site
    Dallas, Texas 75225, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Buenos Aires, C1128AAF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1192AAW, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Buenos Aires, FVH1425, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, 1012, Argentina
  • GSK Investigational Site
    Concepción del Uruguay, 3260, Argentina
  • GSK Investigational Site
    Córdoba, X5003DCE, Argentina
  • GSK Investigational Site
    Formosa, 3600, Argentina
  • GSK Investigational Site
    Lujan de Cuyo, 5509, Argentina
  • GSK Investigational Site
    Luján, 6700, Argentina
  • GSK Investigational Site
    Mar del Plata, 7600, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, 5577, Argentina
  • GSK Investigational Site
    Mendoza, M5500, Argentina
  • GSK Investigational Site
    Quilmes, 1878, Argentina
  • GSK Investigational Site
    Rosario, 2000, Argentina
  • GSK Investigational Site
    Rosario, S2000 DEJ, Argentina
  • GSK Investigational Site
    Rosario, S2000DBS, Argentina
  • GSK Investigational Site
    San Juan Bautista, 1888, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, T4000AXL, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Bruce, Australian Capital Territory 2617, Australia
  • GSK Investigational Site
    Blacktown, New South Wales 2148, Australia
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Kanwal, New South Wales 2259, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2035, Australia
  • GSK Investigational Site
    Brisbane, Queensland 4006, Australia
  • GSK Investigational Site
    Osborne Park, Western Australia 6017, Australia
  • GSK Investigational Site
    Spearwood, Western Australia 6163, Australia
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
  • GSK Investigational Site
    Trois-Rivières, Quebec G9A 4P3, Canada
  • GSK Investigational Site
    Chancheng District, Foshan City 528031, China
  • GSK Investigational Site
    Liwan District, Guangzhou 510160, China
  • GSK Investigational Site
    North Street, Jiangmen City 52900, China
  • GSK Investigational Site
    Nanshan District, 518067, China
  • GSK Investigational Site
    Zhuhai, 519099, China
  • GSK Investigational Site
    Fukuoka, 802-0083, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 816-0813, Japan
  • GSK Investigational Site
    Fukuoka, 820-8505, Japan
  • GSK Investigational Site
    Fukuoka, 832-0059, Japan
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Hiroshima, 730-0013, Japan
  • GSK Investigational Site
    Hiroshima, 730-0853, Japan
  • GSK Investigational Site
    Hiroshima, 733-0002, Japan
  • GSK Investigational Site
    Hyōgo, 651-0053, Japan
  • GSK Investigational Site
    Kagawa, 761-8073, Japan
  • GSK Investigational Site
    Kagoshima, 890-0053, Japan
  • GSK Investigational Site
    Kanagawa, 252-0143, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Kumamoto, 862-0965, Japan
  • GSK Investigational Site
    Matsuyama, 790-0925, Japan
  • GSK Investigational Site
    Miyagi, 980-0871, Japan
  • GSK Investigational Site
    Miyazaki, 880-2112, Japan
  • GSK Investigational Site
    Miyazaki, 889-4304, Japan
  • GSK Investigational Site
    Nagaoka-Shi, 940-0087, Japan
  • GSK Investigational Site
    Niigata, 950-0088, Japan
  • GSK Investigational Site
    Okawa-shi, 831-0016, Japan
  • GSK Investigational Site
    Ōita, Japan
  • GSK Investigational Site
    Shinjuku-kuTokyo, 160-0021, Japan
  • GSK Investigational Site
    Tokyo, 105-0001, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    Tokyo, 145-0063, Japan
  • GSK Investigational Site
    Tokyo, 157-0066, Japan

Showing the first 100 of 117 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Noorduyn SG, Oppenheimer JJ, Moore AC, Nagase H, Crawford J, Poddar A, Boon V, Brown N, Slade D, Garcia G, Baptist AP, Penz E. Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial. Adv Ther. 2026 Jul 20. doi: 10.1007/s12325-026-03721-1. Online ahead of print. PubMed 42474701 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2025, 15 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 15 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 18, 2024
StartActual
Apr 16, 2024
Primary completionActual
Jul 28, 2025
CompletionEst.
Jun 14, 2027was Mar 2027
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • GSK Investigational Site · Orlando, United States
  • GSK Investigational Site · DuBois, United States
Show 2 removed
  • GSK Investigational Site · Florida City, United States
  • GSK Investigational Site · Miami, United States
Oct 6, 2026
Study completion
Mar 31, 2027→Jun 14, 2027
Oct 6, 2026
Enrollment
1366→1358
Oct 6, 2026
Interventions
Arms added: Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]·Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA]; arms removed: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI)·Inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA)
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline (CFB) in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) at Week 24Time frame: Baseline (Day 1), and at Week 24 → Baseline (Day 1) and at Week 24
Oct 6, 2026
Documents
Secondary outcomes
21 edited, 9 added, 10 more
What changed in the outcomes
  • EditedNumberPercentage of participants achieving ≥Participants Achieving Greater Than Equal to (>=) 0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) afterat Week 24 weeks of treatmentTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and at Week 24
  • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpointComposite Endpoint (optimizedOptimized) afterat Week 52 weeks of treatmentTime frame: Up to 52 weeks → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) afterat Week 52 weeks of treatmentTime frame: Baseline (Day 1), and Week 52 → Baseline (Day 1) and at Week 52
  • EditedNumberPercentage of participants achieving ≥Participants Achieving >= 0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the ACQ-7 afterScore at Week 52 weeks of treatmentTime frame: Week 52 → Baseline (Day 1) and at Week 52
  • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the Asthma Control QuestionnaireACQ-6 (ACQ-6) afterScore at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the ACQ-5 after 24 and6 Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedChange from baselineFrom Baseline (CFB) in the ACQ-5 total score after 24 and7 Total Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline (CFB) in the ACQ-6 total score afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedChange from baselineFrom Baseline (CFB) in the Asthma Control Test (ACT) score afterScore at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpoint among thoseComposite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA priorPrior to randomizationRandomization at Week 52Time frame: Week 52 → Baseline (Day 1) and at Week 52
  • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpoint among thoseComposite Endpoint (Optimized) Subset on Participants Receiving no treatment priorTreatment Prior to randomizationRandomization at Week 52Time frame: Up to 52 weeks → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) total scores afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedChange from baselineFrom Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) domain scores after 24 andTotal Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline (CFB) in the four domainsFour Domains of the asthmaAsthma-specific adaptationAdaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire (WPAI:Asthma) afterat Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) among participantsat Week 24 Among Participants on budesonideICS/formoterol priorLABA Prior to randomizationRandomizationTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and Week 24
  • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 points improvement from baselinePoints Improvement (Decrease) From Baseline for ACQ-7 among participantsat Week 24 Among Participants on ICS/LABA priorPrior to randomizationRandomizationTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score among participants on ICS/LABA prior to randomization6 Total Score at Week 52Time frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) at Week 24 for participants withParticipants With no treatment priorTreatment Prior to randomization.RandomizationTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and Week 24
  • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 points improvement from baselinePoints Improvement (Decrease) From Baseline for ACQ-7 for participants with no treatment priorat Week 52 Among Participants on ICS/LABA Prior to randomization.RandomizationTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
  • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score for participants with no treatment prior to randomization.5 Total Score at Week 24Time frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
  • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24Time frame: Baseline (Day 1) and at Week 24
  • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52Time frame: Baseline (Day 1) and at Week 52
  • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24Time frame: Baseline (Day 1) and at Week 24
  • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52Time frame: Baseline (Day 1) and at Week 52
  • AddedPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24Time frame: Baseline (Day 1) and at Week 24
  • AddedPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52Time frame: Baseline (Day 1) and at Week 52
  • AddedChange From Baseline (CFB) in the ACQ-5 Total Score at Week 52Time frame: Baseline (Day 1) and at Week 52
  • AddedChange From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52Time frame: Baseline (Day 1) and at Week 52
  • AddedChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24Time frame: Baseline (Day 1) and at Week 24
  • …and 10 more, on the record history on ClinicalTrials.gov ↗
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • GSK Investigational Site · Orlando, United States
    • GSK Investigational Site · DuBois, United States
    Show 2 removed
    • GSK Investigational Site · Florida City, United States
    • GSK Investigational Site · Miami, United States
    Study completion Mar 31, 2027→Jun 14, 2027
    Enrollment 1366→1358
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline (CFB) in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) at Week 24Time frame: Baseline (Day 1), and at Week 24 → Baseline (Day 1) and at Week 24
    Secondary outcomes 21 edited, 9 added, 10 more
    What changed in the outcomes
    • EditedNumberPercentage of participants achieving ≥Participants Achieving Greater Than Equal to (>=) 0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the Asthma Control Questionnaire-7 (ACQ-7) afterat Week 24 weeks of treatmentTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and at Week 24
    • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpointComposite Endpoint (optimizedOptimized) afterat Week 52 weeks of treatmentTime frame: Up to 52 weeks → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) afterat Week 52 weeks of treatmentTime frame: Baseline (Day 1), and Week 52 → Baseline (Day 1) and at Week 52
    • EditedNumberPercentage of participants achieving ≥Participants Achieving >= 0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the ACQ-7 afterScore at Week 52 weeks of treatmentTime frame: Week 52 → Baseline (Day 1) and at Week 52
    • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the Asthma Control QuestionnaireACQ-6 (ACQ-6) afterScore at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 point improvement from baselinePoint Improvement (Decrease) From Baseline for the ACQ-5 after 24 and6 Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedChange from baselineFrom Baseline (CFB) in the ACQ-5 total score after 24 and7 Total Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline (CFB) in the ACQ-6 total score afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedChange from baselineFrom Baseline (CFB) in the Asthma Control Test (ACT) score afterScore at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpoint among thoseComposite Endpoint (Optimized) Subset on Participants Receiving ICS/LABA priorPrior to randomizationRandomization at Week 52Time frame: Week 52 → Baseline (Day 1) and at Week 52
    • EditedNumberPercentage of participants achievingParticipants Achieving the composite endpoint among thoseComposite Endpoint (Optimized) Subset on Participants Receiving no treatment priorTreatment Prior to randomizationRandomization at Week 52Time frame: Up to 52 weeks → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) total scores afterTotal Score at Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedChange from baselineFrom Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) domain scores after 24 andTotal Score at Week 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline (CFB) in the four domainsFour Domains of the asthmaAsthma-specific adaptationAdaptation of the Work Productivity and Activity Impairment (WPAI) Questionnaire (WPAI:Asthma) afterat Week 24 and 52 weeks of treatmentTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) among participantsat Week 24 Among Participants on budesonideICS/formoterol priorLABA Prior to randomizationRandomizationTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and Week 24
    • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 points improvement from baselinePoints Improvement (Decrease) From Baseline for ACQ-7 among participantsat Week 24 Among Participants on ICS/LABA priorPrior to randomizationRandomizationTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score among participants on ICS/LABA prior to randomization6 Total Score at Week 52Time frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline in trough forced expiratory volumeTrough Forced Expiratory Volume in 1 secondSecond (FEV1) at Week 24 for participants withParticipants With no treatment priorTreatment Prior to randomization.RandomizationTime frame: Baseline (Day 1), and Week 24 → Baseline (Day 1) and Week 24
    • EditedNumberPercentage of participants achieving ≥Participants Achieving >=0.5 points improvement from baselinePoints Improvement (Decrease) From Baseline for ACQ-7 for participants with no treatment priorat Week 52 Among Participants on ICS/LABA Prior to randomization.RandomizationTime frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 52
    • EditedChange from baselineFrom Baseline (CFB) in the ACQ-7 total score for participants with no treatment prior to randomization.5 Total Score at Week 24Time frame: Baseline (Day 1), Week 24 and Week 52 → Baseline (Day 1) and at Week 24
    • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 24Time frame: Baseline (Day 1) and at Week 24
    • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 100 mL at Week 52Time frame: Baseline (Day 1) and at Week 52
    • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 24Time frame: Baseline (Day 1) and at Week 24
    • AddedPercentage of Participants With Change From Baseline in Trough FEV1 >= 0 mL at Week 52Time frame: Baseline (Day 1) and at Week 52
    • AddedPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 Score at Week 24Time frame: Baseline (Day 1) and at Week 24
    • AddedPercentage of Participants Achieving >=0.5 Point Improvement (Decrease) From Baseline for the ACQ-5 at Week 52Time frame: Baseline (Day 1) and at Week 52
    • AddedChange From Baseline (CFB) in the ACQ-5 Total Score at Week 52Time frame: Baseline (Day 1) and at Week 52
    • AddedChange From Baseline (CFB) in the Asthma Control Test (ACT) Score at Week 52Time frame: Baseline (Day 1) and at Week 52
    • AddedChange From Baseline (CFB) in the Asthma Quality of Life Questionnaire (AQLQ-12) Domain Score at Week 24Time frame: Baseline (Day 1) and at Week 24
    • …and 10 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arms added: Fluticasone Furoate [FF]/ Umeclidinium [UMEC]/ Vilanterol [VI]·Inhaled Corticosteroid [ICS]/Long-acting beta-2 agonist [LABA]; arms removed: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI)·Inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06372496
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Apr 16, 2024
Primary completion
Jul 28, 2025
Completion
Jun 14, 2027 (estimated)
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Umeclidinium bromide · Vilanterol trifenatate

Start the discussion